Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In our previous study, osteosarcoma advanced locally, and metastasis was promoted through the secretion of large number of small extracellular vesicles, followed by suppressing osteoclastogenesis via the upregulation of microRNA (miR)-146a-5p. An additional 12 miRNAs in small extracellular vesicles were also detected ≥6× as frequently in high-grade malignancy with the capacity to metastasize as in those with a low metastatic potential. However, the utility of these 13 miRNAs for determining the prognosis or diagnosis of osteosarcoma has not been validated in the clinical setting. In the present study, the utility of these miRNAs as prognostic and diagnostic markers was therefore assessed. In total, 30 patients with osteosarcoma were retrospectively reviewed, and the survival rate was compared according to the serum miRNA levels in 27 patients treated with chemotherapy and surgery. In addition, to confirm diagnostic competency for osteosarcoma, the serum miRNA levels were compared with those in patients with other bone tumors (n=112) and healthy controls (n=275). The patients with osteosarcoma with high serum levels of several miRNAs (miR-146a-5p, miR-1260a, miR-487b-3p, miR-1260b and miR-4758-3p) exhibited an improved survival rate compared with those with low levels. In particular, patients with high serum levels of miR-1260a exhibited a significantly improved overall survival rate, metastasis-free survival rate and disease-free survival rate compared with those with low levels. Thus, serum miR-1260a may potentially be a prognostic marker for patients with osteosarcoma. Moreover, patients with osteosarcoma had higher serum miR-1261 levels than those with benign or intermediate-grade bone tumors and thus may be a potential therapeutic target, in addition to being useful for differentiating whether or not a bone tumor is high-grade. A larger investigation is required to clarify the actual utility of these miRNAs in the clinical setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157352 | PMC |
| http://dx.doi.org/10.3892/ol.2023.13808 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving oncological outcomes for pelvic bone sarcomas: Is it possible?
Eur J Surg Oncol
August 2025
Royal Orthopaedic Hospital, Birmingham, United Kingdom.
Introduction: Pelvic bone sarcomas are rare, heterogeneous malignancies that present significant diagnostic and therapeutic challenges. Despite advances in imaging, surgical navigation, and multidisciplinary care, it remains unclear whether these innovations have improved outcomes across all histiotypes.
Material And Methods: We conducted a retrospective cohort study of 475 patients surgically treated for primary pelvic bone sarcomas between 2003 and 2022.
Limb salvage surgery with cryotherapy in osteosarcoma of the femoral shaft: A case report.
Int J Surg Case Rep
August 2025
Department of Anatomical Pathology, Faculty of Medicine, University of Sumatera Utara, Adam Malik General Hospital, Indonesia.
Introduction And Importance: Osteosarcoma is the most common primary malignant bone tumor, primarily affecting children and adolescents. Treatment is often challenging due to availability of modalities across hospitals. This study reports a case of osteosarcoma located in the midshaft of the femur.
View Article and Find Full Text PDFOrtho-bridge system for the treatment of Vancouver type B1 periprosthetic femoral fractures based on three dimensional printing.
Int Orthop
September 2025
Department of the Second Medical Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
Objective: This study aims to evaluate the clinical outcomes of Vancouver B1 periprosthetic femoral fractures (PFF) treated with the Ortho-bridge system (OBS) internal fixation and assess the potential benefits of 3D printing technology in preoperative planning and surgical execution for these cases.
Method: This retrospective study analyzed 55 consecutive Vancouver B1 periprosthetic femoral fracture cases treated surgically at Yan'an Affiliated Hospital of Kunming Medical University (2014-2022) with minimum 1-year follow-up. Patients were divided into conventional ORIF (n = 21) and OBS fixation groups (n = 34), with the OBS group further stratified into standard procedure (n = 18) and 3D-printing-assisted (n = 16) subgroups.
RNF207 promotes the proliferation, migration and invasion of osteosarcoma through KCNQ1 mediated activation of ERK/MEK signaling pathway.
Int Immunopharmacol
September 2025
Department of Orthopaedics, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China. Electronic address:
Background: Ring finger protein 207 (RNF207) is an E3 ubiquitin ligase that regulates the stability and activity of target proteins via ubiquitination and non-proteolytic mechanisms. However, its role in osteosarcoma pathogenesis and association with patient prognosis remain poorly understood.
Methods: We integrated bioinformatics analyses of public databases with assayal validation in osteosarcoma cell lines and clinical tissue samples to assess RNF207 expression and its prognostic significance.
Anti-tumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expression.
Mol Cancer Ther
September 2025
Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate (ADC) with efficacy across adult cancers exhibiting variable HER2 expression. Prior studies demonstrating HER2 expression in osteosarcoma (OS) motivated a clinical trial of T-DXd in pediatric and adolescent/young adults with OS but was terminated early for inactivity. We evaluated the activity of T-DXd using OS patient-derived xenograft (PDX) models and found a 22% objective response rate despite no detectable HER2 expression across PDXs tested.
View Article and Find Full Text PDF